| Jewish Senior Services | |
| 4200 Park Avenue, Bridgeport, Connecticut 06604 | |
| (203) 365-6400 | |
| Name | Jewish Senior Services |
|---|---|
| Location | 4200 Park Avenue, Bridgeport, Connecticut |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 360 |
| Occupancy Rate | 73% |
| Medicare ID (CCN) | 075353 |
| Legal Business Name | Jewish Home For The Elderly Of Fairfield County Incorporated |
| Ownership Type | Non Profit - Corporation |
| NPI Number | 1083602346 |
| Organization Name | JEWISH HOME FOR THE ELDERLY OF FAIRFIELD COUNTY INCORPORATED |
| Doing Business As | JEWISH SENIOR SERVICES |
| Address | 4200 Park Ave, Bridgeport, CT 06604 |
| Phone Number | 203-365-6400 |
News Archive
Stem cell research at the University of California, Riverside is about to gather speed thanks to the establishment of a new Stem Cell Core Facility (SCCF) - a shared facility providing infrastructure, equipment, and trained personnel for doing stem cell research that ordinarily would not be available in most laboratories.
UT Southwestern Medical Center and the faculty of health sciences of the University of Cape Town in South Africa, signed a five-year affiliation agreement today to collaborate on faculty and student exchanges, joint research and training activities and other educational opportunities.
Study findings show distinct subtypes of antineutrophil cytoplasmic antibody-associated vasculitis, distinguished by the target of autoantigen reactivity.
Syndax Pharmaceuticals, Inc., a late-stage oncology company focused on the clinical development of epigenetic therapies in solid tumors, announced that previously reported results from ENCORE 401, a randomized, placebo controlled Phase 2 study of erlotinib with or without entinostat in advanced non-small cell lung cancer patients were published in the Journal of Clinical Oncology (JCO).
› Verified 6 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Stem cell research at the University of California, Riverside is about to gather speed thanks to the establishment of a new Stem Cell Core Facility (SCCF) - a shared facility providing infrastructure, equipment, and trained personnel for doing stem cell research that ordinarily would not be available in most laboratories.
UT Southwestern Medical Center and the faculty of health sciences of the University of Cape Town in South Africa, signed a five-year affiliation agreement today to collaborate on faculty and student exchanges, joint research and training activities and other educational opportunities.
Study findings show distinct subtypes of antineutrophil cytoplasmic antibody-associated vasculitis, distinguished by the target of autoantigen reactivity.
Syndax Pharmaceuticals, Inc., a late-stage oncology company focused on the clinical development of epigenetic therapies in solid tumors, announced that previously reported results from ENCORE 401, a randomized, placebo controlled Phase 2 study of erlotinib with or without entinostat in advanced non-small cell lung cancer patients were published in the Journal of Clinical Oncology (JCO).
› Verified 6 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 1 |
| Total Amount of Fines in Dollars | $10793 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 1 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 13.18 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 6.12 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 62.76 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 1.95 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 6.11 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 1.99 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 4.01 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 88.08 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 20.02 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 67.85 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 0.88 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 26.43 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 16.36 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 4.87 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 97.45 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 64.83 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 80.54 | 82.93 |
News Archive
Stem cell research at the University of California, Riverside is about to gather speed thanks to the establishment of a new Stem Cell Core Facility (SCCF) - a shared facility providing infrastructure, equipment, and trained personnel for doing stem cell research that ordinarily would not be available in most laboratories.
UT Southwestern Medical Center and the faculty of health sciences of the University of Cape Town in South Africa, signed a five-year affiliation agreement today to collaborate on faculty and student exchanges, joint research and training activities and other educational opportunities.
Study findings show distinct subtypes of antineutrophil cytoplasmic antibody-associated vasculitis, distinguished by the target of autoantigen reactivity.
Syndax Pharmaceuticals, Inc., a late-stage oncology company focused on the clinical development of epigenetic therapies in solid tumors, announced that previously reported results from ENCORE 401, a randomized, placebo controlled Phase 2 study of erlotinib with or without entinostat in advanced non-small cell lung cancer patients were published in the Journal of Clinical Oncology (JCO).
› Verified 6 days ago
Jewish Senior Services Location: 4200 Park Avenue, Bridgeport, Connecticut 06604 Phone: (203) 365-6400 | |
Northbridge Health Care Center Location: 2875 Main Street, Bridgeport, Connecticut 06606 Phone: (203) 336-0232 | |
Springs At Watermark 3030 Park, The Location: 3030 Park Avenue, Bridgeport, Connecticut 06604 Phone: (203) 374-5611 |